MMP7 and plasma cell myeloma: The study found that MMP-7-deficient myeloma-bearing mice had a significantly higher tumor load and osteolytic bone disease compared to their wild-type counterparts, and clinical evidence supported the in vivo murine myeloma studies as well, which demonstrated a marked decrease in MMP-7 activity observed in MM patients.